Dong-A's Stillen showing robust sales in first quarter

Dong-A Pharmaceutical' said it anti-ulcerant drug Stillen recorded brisk sales of 14.0 billion won in the first quarter of this year, thanks to superior efficacy and intensive marketing in the domestic market where homegrown new medicines cannot be viable amid deep distrust on their efficacy.

Stilen is a mucoprotectant agent derived from artemisia vulgaris and was developed through an intens...